Altered intestinal ACE2 levels are associated with inflammation, severe disease and response to anti-cytokine therapy in IBD

The host receptor for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2) is highly expressed in small bowel (SB). Our aim was to identify factors influencing intestinal ACE2 expression in Crohn’s disease (CD), ulcerative colitis (UC) and non-inflammatory bowel disease (non-IBD) controls.